• Ahrendt SA, Pitt HA, Nakeeb A, Klein AS, Lillemoe KD, Kalloo AN, Cameron JL 1999 Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J. Gastrointest. Surg. 3: 357-367.

• Arakawa Y, Kobayashi H, Ozaki T, Ariga H, Matsuo Y, Honda T, Arai T, Kurosu Y, Morita K, Konuma H, et al 1984 Serum determination of CA 19-9 in patients with digestive cancers and its diagnostic evaluation. Gan. To. Kagaku. Ryoho. 11: 917-925.

• Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Yoshidome H, Kato A, Miyazaki M 2005 Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology 52: 722-724.

• Augarten A, Berman H, Aviram M, Diver-Habber A, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Kerem BS, Theodor L, Paret G, Yahav Y 2003 Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests. Clin. Exp. Med. 3: 119-123. *

• Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L 2006 Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int. J. Urol. 13: 1380-1384. *

• Bergquist A 2003 Tumor markers and genetic markers in the diagnosis of bile duct carcinoma. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 91. October 15-16. *

• Bergquist A, Glaumann H, Persson B, Broome U 1998 Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27: 311-316. *

• Bettinardi N, Felicetta I, Tomasi PA, Colombo C 2003 Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis. Clin. Chem. Lab. Med. 41: 311-316.

• Bhargava N, Qureshi J, Vakil N 2007 Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals. Am. J. Gastroenterol. 102: 1146-1150. *

• Bjornsson E, Kilander A, Olsson R 1999 CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19: 501-508. *

• Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R 2004 Dominant strictures in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 99: 502-508. *

• Boberg KM, Schrumpf E 2004 Diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 6: 52-59.

• Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD 2004 Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 99: 523-526. *

• Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, Weiss ST, Hasday J, Lilly CM, Ford JG, Drazen JM 1999 Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am. J. Respir. Crit. Care Med. 160: 919-922. *

• Calisto J, Tagle M, Bedoya P, Scavino Y, Luna E, Poletti L, Targarona J 2008 Autoimmune hepatitis with elevation of CA 19-9 and normalization with immunosuppresant treatment: case report and review of the literature. Rev. Gastroenterol. Peru 28: 167-170.

• Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C 2004 Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 66: 296-302.

• Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C 2004 CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol. 25: 228-234.

• Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H 2000 Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31: 7-11. *

• Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.

• Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD 2008 Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology Jun 9 [Epub ahead of print].

• Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC 2005 Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J. Surg. Res. 124: 169-174. *

• Curley SA 2003 CHAPTER 99. Diagnosis and Management of Biliary Tract Cancer. (http://www.cancer.org/downloads/PUB/DOCS/SECTION29/99.pdf) SECTION 29. Neoplasms of the Alimentary Canal. pp. 1423-1430. *

• Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16. *

• Dubaniewicz A, Dubaniewicz A 2003 Cholangiocarcinoma - bile ducts cancer. Wiad. Lek. 56: 57-60.

• Eklund C, Huttunen R, Syrjanen J, Laine J, Vuento R, Hurme M 2006 Polymorphism of the C-reactive protein gene is associated with mortality in bacteraemia. Scand. J. Infect. Dis. 38: 1069-1073. *

• Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, Nawata H, Watanabe T 2004 Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig. Liver Dis. 36: 622-627.

• Evert M, Seiler C, Dombrowski F 2005 Aberrant acinar cell CA 19-9 expression and peri-insular acinar cell alterations in an adult human pancreas. Virchows Arch. 446: 68-72. *

• Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W 2007 Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 52: 3123-3135. *

• Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA 1995 CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl. Surg. 1: 94-98.

• Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.

• Furmanczyk PS, Grieco VS, Agoff SN 2005 Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am. J. Clin. Pathol. 124: 355-360.

• Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL 2006 C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J. Gastroenterol. 12: 5495-5500. *

• Ghazale A, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Clain JE, Pearson RK, Pelaez-Luna M, Petersen BT, Swaroop Vege S, Farnell MB 2007 Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am. J. Gastroenterol. 102: 1646-1653. *

• Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R 2000 Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int. J. Biol. Markers 15: 226-230.

• Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM 2006 New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 24: 252-258. *

• Goonetilleke KS, Siriwardena AK 2007 Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33: 266-270.

• Gores GJ 2000 Early detection and treatment of cholangiocarcinoma. Liver Transpl. 6: S30-S34. *

• Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR 2004 Treatment endpoints for advanced cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 4-5. *

• Gronowitz E, Pitkanen S, Kjellmer I, Heikinheimo M, Strandvik B 2003 Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis. Acta Paediatr. 92: 1267-1271. *

• Gross JB Jr, Kumar N 2003 Simultaneous occurrence of PSC and MS in a patient. Dig. Dis. Sci. 48: 1397. *

• Grote T, Logsdon CD 2007 Progress on molecular markers of pancreatic cancer. Curr. Opin. Gastroenterol. 23: 508-514.

• Halme L, Karkkainen P, Isoniemi H, Makisalo H, von Bogulawski K, Hockerstedt K 1999 Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen. Scand. J. Gastroenterol. 34: 426-431. *

• Hardt PD, Killinger A, Nalop J, Schnell-Kretschmer H, Zekorn T, Klor HU 2002 Chronic pancreatitis and diabetes mellitus. A retrospective analysis of 156 ERCP investigations in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Pancreatology 2: 30-33.

• Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB 2006 Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 82: 1703-1707.

• Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, Paoli MD, Plebani M, Tulassay Z 2008 Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8: 194. *

• Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, Wahren B, Broome U 1999 A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J. Hepatol. 30: 669-673. *

• Ikehata A, Sakuma T 2000 Gastric duplication cyst with markedly elevated concentration of carbohydrate antigen 19-9. Am. J. Gastroenterol. 95: 842-843. *

• Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, Sun WH, Ji M 2004 Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J. Gastroenterol. 10: 1675-1677. *

• John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR 2006 Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig. Surg. 23: 319-324.

• Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR 2007 The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J. Surg. Res. 140: 31-35. *

• Katsanos KH, Kitsanou M, Christodoulou DK, Tsianos EV 2002 High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur. J. Intern. Med. 13: 132-135.

• Kawamoto S, Siegelman SS, Hruban RH, Fishman EK 2004 Lymphoplasmacytic sclerosing pancreatitis with obstructive jaundice: CT and pathology features. AJR Am. J. Roentgenol. 183: 915-921. *

• Khalaf H, Mourad W, El-Sheikh Y, Abdo A, Helmy A, Medhat Y, Al-Sofayan M, Al-Sagheir M, Al-Sebayel M 2007 Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant. Proc. 39: 1166-1170. *

• Kilickap S, Abali H, Aksoy S, Celik I 2004 CA 19-9 measurement as a screening: higher cost, lower survival. J. Gastroenterol. Hepatol. 19: 1428. *

• Kim T, Grobmyer SR, Dixon LR, Hochwald SN 2008 Isolated lymphoplasmacytic sclerosing pancreatitis involving the pancreatic tail. Am. Surg. 74: 654-658.

• Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A 2004 Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 101: 1609-1615. *

• Lakatos PL, Gyori G, Halasz J, Fuszek P, Papp J, Jaray B, Lukovich P, Lakatos L 2005 Mucocele of the appendix: an unusual cause of lower abdominal pain in a patient with ulcerative colitis. A case report and review of literature. World J. Gastroenterol. 11: 457-459. *

• Lara LF, Levy MJ 2004 Idiopathic recurrent acute pancreatitis. MedGenMed. 6: 10.

• Lauri A, Horton RC, Davidson BR, Burroughs AK, Dooley JS 1993 Endoscopic extraction of bile duct stones: management related to stone size. Gut 34: 1718-1721. *

• Lee H, Lee JK, Kang SS, Choi D, Jang KT, Kim JH, Lee KT, Paik SW, Yoo BC, Rhee JC 2007 Is there any clinical or radiologic feature as a preoperative marker for differentiating mass-forming pancreatitis from early-stage pancreatic adenocarcinoma? Hepatogastroenterology 54: 2134-2140.

• Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, Chantawibul S, Tepaksorn P 2006 Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J. Gastroenterol. 12: 4195-4198. *

• Lempinen M, Isoniemi H, Makisalo H, Nordin A, Halme L, Arola J, Hockerstedt K, Stenman UH 2007 Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J. Hepatol. 47: 677-683. *

• Leung R, Jones IT 2005 Clinical experience with Crohn's disease. ANZ J. Surg. 75: 471-474.

• Leung UC, Wong PY, Roberts RH, Koea JB 2007 Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply? ANZ J. Surg. 77: 355-357. *

• Levy C, Lymp J, Angulo P, Gores GJ, LaRusso N, Lindor KD 2005 The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50: 1734-1740. *

• Lindberg B, Arnelo U, Bergquist A, Thorne A, Hjerpe A, Granqvist S, Hansson LO, Tribukait B, Persson B, Broome U 2002 Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 34: 909-916.

• Liu QC, Gao F, Ou QS, Zhuang ZH, Lin SR, Yang B, Cheng ZJ 2008 Novel mutation and polymorphism of PRSS1 gene in the Chinese patients with hereditary pancreatitis and chronic pancreatitis. Chin. Med. J. (Engl.) 121: 108-111.

• Loi S, Haydon AM, Shapiro J, Schwarz MA, Schneider HG 2004 Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital. Intern. Med. J. 34: 545-550. *

• Ludvigsson JF, Eylert M, Ilonen J, Ludvigson J, Vaarala O 2006 Effect of HLA DQ2, dietary exposure and coeliac disease on the development of antibody response to gliadin in children. Scand. J. Gastroenterol. 41: 919-928. *

• Macfaul GR, Chapman RW 2006 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 22: 288-293.

• Madonia S, Aragona E, Maisano S, Montalbano L, Olivo M, Rossi F, Restivo G, Cottone M 2007 CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test? Dig. Dis. Sci. 52: 1125-1127. *

• Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA 1998 The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann. Clin. Biochem. 35: 99-103.

• Martins EB, Chapman RW 2000 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 16: 444-449.

• Michl P, Pauls S, Gress TM 2006 Evidence-based diagnosis and staging of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 20: 227-251.

• Montalto M, Santoro L, Vastola M, Curigliano V, Ricci R, Vecchio FM, Manna R, Gasbarrini G 2005 Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment. Int. J. Immunopathol. Pharmacol. 18: 603-608.

• Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N 2004 Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis. Colon Rectum 47: 227-232.

• Murray MD, Burton FR, Di Bisceglie AM 2007 Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J. Clin. Gastroenterol. 41: 115-117.

• Nehls O, Gregor M, Klump B 2004 Serum and bile markers for cholangiocarcinoma. Semin. Liver Dis. 24: 139-154.

• Neuberger J 2003 Primary sclerosing cholangitis: indications for transplantation and recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 93-94. October 15-16. *

• Neuberger J 2003 Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121.

• Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P 2005 The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur. J. Surg. Oncol. 31: 164-169.

• Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr 1993 Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin. Proc. 68: 874-879.

• Ohkura H 2004 Clinical usefulness of circulating tumor markers. Gan To Kagaku Ryoho 31: 1131-1134.

• Papachristou GI, Demetris AJ, Craig F, Lee KKW, Rabinovitz M 2004 Cholestatic jaundice and bone lesions in an elderly woman. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 53-57. *

• Parra JL, Kaplan S, Barkin JS 2005 Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level. Dig. Dis. Sci. 50: 694-695. *

• Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ 2000 The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 204-207. *

• Pavai S, Yap SF 2003 The clinical significance of elevated levels of serum CA 19-9. Med. J. Malaysia 58: 667-672.

• Pearce S, Thornes H, Carr D, Tanner A 1994 Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. Gut 35: 707-708. *

• Petersen-Benz C, Stiehl A 2005 Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis. Z. Gastroenterol. 43: 587-590.

• Prall RT, Lindor KD, Wiesner RH, LaRusso NF 2000 Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103.

• Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R 1995 Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108: 865-869. *

• Rocken C, Pross M, Brucks U, Ridwelski K, Roessner A 2000 Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). Arch. Pathol. Lab. Med. 124: 1704-1706. *

• Rumalla A, Petersen BT 2000 Diagnosis and therapy of biliary tract malignancy. Semin. Gastrointest. Dis. 11: 168-173.

• Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P 2004 Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10: 1018-1023. *

• Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Pantazopoulou A, Tsiotos G 2007 EUS-FNA contribution in the identification of autoimmune pancreatitis: a case report. JOP 8: 598-604. *

• Sanchez M, Gomes H, Marcus EN 2006 Elevated CA 19-9 levels in a patient with Mirizzi syndrome: case report. South Med. J. 99: 160-163.

• Schmitt TM, Hughes CB, Bonatti H, Harnois DM, Nguyen JH, Dickson RC, Spivey JR, Steers JL 2005 Gallbladder cancer and liver transplantation. Transpl. Int. 18: 52-55.

• Schneider J, Schulze G 2003 Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res. 23: 5089-5093.

• Schrumpf E, Boberg KM 2002 Endoscopic treatment for primary sclerosing cholangitis? J. Hepatol. 36: 278-279. *

• Schulick RD 2008 Primary sclerosing cholangitis detection of cancer in strictures. J. Gastrointest. Surg. 12: 420-422. *

• Schumacher G, Bechstein WO, Kling N, Lobeck H, Hintze R, Neuhaus P 1997 Bile duct carcinoma in an adenoma in the anastomotic area after hepaticojejunostomy - a case report. Z. Gastroenterol. 35: 1081-1086.

• Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH 2007 Extremely elevated CA19-9 in acute cholangitis. Dig. Dis. Sci. 52: 3140-3142. *

• Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, Abu-Elmaagd K, Madariaga JR, Slivka A, Martini J 2002 Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest. Endosc. 56: 40-47. *

• Steele IL, Levy C, Lindor KD 2007 Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20.

• Stiehl A 2002 Primary sclerosing cholangitis: neoplastic potential in bile ducts, colon and the pancreas? J. Hepatol. 36: 433-434. *

• Stintzing S, Herold C, Hahn EG, Boxberger F 2008 CA 19-9 in the differential diagnosis of pancreatic lesions. Internist (Berl.) 49: 225-227.

• Stroescu C, Herlea V, Dragnea A, Popescu I 2006 The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J. Gastrointestin. Liver Dis. 15: 9-14. *

• Szekanecz E, Sandor Z, Antal-Szalmas P, Soos L, Lakos G, Besenyei T, Szentpetery A, Simkovics E, Szanto J, Kiss E, Koch AE, Szekanecz Z 2007 Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann. N. Y. Acad. Sci. 1108: 359-371. *

• Tellam J, Smith C, Rist M, Webb N, Cooper L, Vuocolo T, Connolly G, Tscharke DC, Devoy MP, Khanna R 2008 Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc. Natl. Acad. Sci. U.S.A. 105: 9319-9324. *

• Tischendorf JJ, Meier PN, Schneider A, Manns MP, Kruger M 2007 Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 42: 1011-1017. *

• Tischendorf JJ, Meier PN, Strassburg CP, Klempnauer J, Hecker H, Manns MP, Kruger M 2006 Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 41: 1227-1234. *

• Toomey DP, Swan N, Torreggiani W, Conlon KC 2007 Autoimmune pancreatitis: medical and surgical management. JOP 8: 335-343. *

• Torok N, Gores GJ 2001 Cholangiocarcinoma. Semin. Gastrointest. Dis. 12: 125-132.

• Uehara M, Manaka D, Baba S, Oji Y, Hirata K, Shimizu M, Noguchi M 2007 Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer. Gan To Kagaku Ryoho 34: 1413-1417.

• Ulla Rocha JL, Alvarez Sanchez MV, Paz Esquete J, Fernandez Salgado E, Alvarez Alvarez C, Vazquez Sanluis MJ, Ledo Barro L, Vazquez Astray E 2007 Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation. JOP 8: 191-197. *

• Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A 2007 Type 2 diabetes mellitus and CA 19-9 levels. World J. Gastroenterol. 13: 5357-5359. *

• Van Beers BE 2008 Diagnosis of cholangiocarcinoma. HPB (Oxford) 10: 87-93. *

• Vij K, Wang HL 2008 Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence. Int. J. Surg. Pathol. 16: 194-198.

• Vilar R, Coelho H, Rodrigues E, Gama MJ, Rivera I, Taioli E, Lechner MC 2007 Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease. Eur. J. Neurol. 14: 156-161.

• Watine J, Friedberg B 2004 Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin. Chim. Acta 345: 1-15. *

• Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP 2008 The challenges in primary sclerosing cholangitis: aetiopathogenesis, autoimmunity, management and malignancy? J. Hepatol. 48: S38-S57. *

• Welsch T, Kleeff J, Esposito I, Buchler MW, Friess H 2006 Autoimmune pancreatitis associated with a large pancreatic pseudocyst. World J. Gastroenterol. 12: 5904-5906. *

• Yang SK, Lim J, Chang HS, Lee I, Li Y, Liu J, Song K 2008 Association of TNFSF15 with Crohn's disease in Koreans. Am. J. Gastroenterol. 103: 1437-1442. *

• Yoon JH, Gores GJ 2003 Diagnosis, staging, and treatment of cholangiocarcinoma. Curr. Treat. Options Gastroenterol. 6: 105-112.

• Yoshida EM, Scudamore CH, Erb SR, Owen DA, Silver HK 1995 Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis. Can. J. Surg. 38: 83-86.

• Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ 2008 Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J. Gastroenterol. 14: 3750-3753. *

• Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, Schumpelick V, Buell U 2000 Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand. J. Gastroenterol. 35: 883-888. *

Number of references = 127

www psc-literature.org